Literature DB >> 27701909

Efficacy of an anti-CD22 antibody-monomethyl auristatin E conjugate in a preclinical xenograft model of precursor B-cell acute lymphoblastic leukemia.

Sakiko Yoshida1, Emily Tuscano2, Connie Duong1, Jong Chung1, Yueju Li3, Laurel Beckett3, Joseph M Tuscano2, Noriko Satake1.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2016        PMID： 27701909      PMCID： PMC5457839          DOI： 10.1080/10428194.2016.1235273

Source DB:  PubMed          Journal:  Leuk Lymphoma        ISSN： 1026-8022


× No keyword cloud information.
  15 in total

1.  Differential cellular internalization of anti-CD19 and -CD22 immunotoxins results in different cytotoxic activity.

Authors:  Xing Du; Richard Beers; David J Fitzgerald; Ira Pastan
Journal:  Cancer Res       Date:  2008-08-01       Impact factor: 12.701

2.  A Novel Anti-CD22 Anthracycline-Based Antibody-Drug Conjugate (ADC) That Overcomes Resistance to Auristatin-Based ADCs.

Authors:  Shang-Fan Yu; Bing Zheng; MaryAnn Go; Jeff Lau; Susan Spencer; Helga Raab; Robert Soriano; Suchit Jhunjhunwala; Robert Cohen; Michele Caruso; Paul Polakis; John Flygare; Andrew G Polson
Journal:  Clin Cancer Res       Date:  2015-04-03       Impact factor: 12.531

3.  Childhood and adolescent cancer statistics, 2014.

Authors:  Elizabeth Ward; Carol DeSantis; Anthony Robbins; Betsy Kohler; Ahmedin Jemal
Journal:  CA Cancer J Clin       Date:  2014-01-31       Impact factor: 508.702

Review 4.  New developments for antibody-drug conjugate-based therapeutic approaches.

Authors:  Bart Ecg de Goeij; John M Lambert
Journal:  Curr Opin Immunol       Date:  2016-03-07       Impact factor: 7.486

5.  The same epitope on CD22 of B lymphocytes mediates the adhesion of erythrocytes, T and B lymphocytes, neutrophils, and monocytes.

Authors:  P Engel; Y Nojima; D Rothstein; L J Zhou; G L Wilson; J H Kehrl; T F Tedder
Journal:  J Immunol       Date:  1993-06-01       Impact factor: 5.422

6.  Chemoimmunotherapy reinduction with epratuzumab in children with acute lymphoblastic leukemia in marrow relapse: a Children's Oncology Group Pilot Study.

Authors:  Elizabeth A Raetz; Mitchell S Cairo; Michael J Borowitz; Susan M Blaney; Mark D Krailo; Tarek A Leil; Joel M Reid; David M Goldenberg; William A Wegener; William L Carroll; Peter C Adamson
Journal:  J Clin Oncol       Date:  2008-08-01       Impact factor: 44.544

7.  DCDT2980S, an anti-CD22-monomethyl auristatin E antibody-drug conjugate, is a potential treatment for non-Hodgkin lymphoma.

Authors:  Dongwei Li; Kirsten Achilles Poon; Shang-Fan Yu; Randall Dere; MaryAnn Go; Jeffrey Lau; Bing Zheng; Kristi Elkins; Dimitry Danilenko; Katherine R Kozak; Pamela Chan; Josefa Chuh; Xiaoyan Shi; Denise Nazzal; Franklin Fuh; Jacqueline McBride; Vanitha Ramakrishnan; Ruth de Tute; Andy Rawstron; Andrew S Jack; Rong Deng; Yu-Waye Chu; David Dornan; Marna Williams; William Ho; Allen Ebens; Saileta Prabhu; Andrew G Polson
Journal:  Mol Cancer Ther       Date:  2013-04-18       Impact factor: 6.261

8.  The HB22.7-vcMMAE antibody-drug conjugate has efficacy against non-Hodgkin lymphoma mouse xenografts with minimal systemic toxicity.

Authors:  Mastewal Abuhay; Jason Kato; Emily Tuscano; Gustavo A Barisone; Ranjit S Sidhu; Robert T O'Donnell; Joseph M Tuscano
Journal:  Cancer Immunol Immunother       Date:  2016-08-09       Impact factor: 6.968

9.  Second malignant neoplasms after treatment of childhood acute lymphoblastic leukemia.

Authors:  Kjeld Schmiegelow; Mette Frandsen Levinsen; Andishe Attarbaschi; Andre Baruchel; Meenakshi Devidas; Gabriele Escherich; Brenda Gibson; Christiane Heydrich; Keizo Horibe; Yasushi Ishida; Der-Cherng Liang; Franco Locatelli; Gérard Michel; Rob Pieters; Caroline Piette; Ching-Hon Pui; Susana Raimondi; Lewis Silverman; Martin Stanulla; Batia Stark; Naomi Winick; Maria Grazia Valsecchi
Journal:  J Clin Oncol       Date:  2013-05-20       Impact factor: 44.544

Review 10.  Current Phase II antibody-drug conjugates for the treatment of lymphoid malignancies.

Authors:  Tadeusz Robak; Ewa Robak
Journal:  Expert Opin Investig Drugs       Date:  2014-04-07       Impact factor: 6.206
View more
  1 in total

Review 1.  Therapeutic Monoclonal Antibodies and Antibody Products: Current Practices and Development in Multiple Myeloma.

Authors:  Francesca Bonello; Roberto Mina; Mario Boccadoro; Francesca Gay
Journal:  Cancers (Basel)       Date:  2019-12-19       Impact factor: 6.639
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.